OR WAIT null SECS
Jill Wechsler is Pharm Exec's Washington Corespondent
April 21, 2016.
The good news about FDA’s breakthrough drug initiative is that it actually appears to be accelerating clinical development of highly promising new therapies, according to recent analysis by Friends of Cancer Research (FOCR) .
Read Jill Wechsler's view in Applied Clinical Trials.